Navigation Links
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Date:2/13/2008

Mexico is the First Latin American Country to Approve Treatment

BASINGSTOKE, England and CAMBRIDGE, Massachusetts, February 13 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY)(TSX: SHQ), the global specialty biopharmaceutical company, announced that ELAPRASE(R) (idursulfase), a human enzyme replacement therapy for the treatment of Hunter syndrome, has been approved for commercial sale by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS). Mexico is the tenth-largest pharmaceutical market in the world(1) and the first Latin American country to approve ELAPRASE.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a serious, life-threatening genetic condition mainly affecting males that results from an absence of, or deficiency in, the lysosomal enzyme iduronate-2-sulfatase. Without sufficient amounts of this enzyme, cellular waste products accumulate in tissues and organs, which then begin to malfunction, leading to severe clinical complications and early mortality.

ELAPRASE, developed by Shire Human Genetic Therapies (HGT), is the first and only enzyme replacement therapy approved for people suffering from Hunter syndrome. The medicine is given as a weekly infusion and is designed to replace the deficient iduronate-2-sulfatase enzyme.

"The approval of ELAPRASE in Mexico marks a significant milestone because for the first time, Hunter syndrome patients in Mexico have access to treatment," said Sylvie Gregoire, President of Shire HGT, the Shire business unit focused on genetic diseases. "This approval also underscores our dedication and commitment to provide meaningful treatments for patients suffering from serious and often neglected diseases around
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Genzyme Receives Approval to Market Elaprase(R) in Japan
3. Clexane(R)/Lovenox(R) Approved in Japan
4. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Biomoda Announces Collaborative Agreement With New Mexico Tech
10. Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean
11. Prestigious Bioethics Award for Scholar from Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/20/2014)... 20, 2014 Local veterinary surgeon, Dr. ... investigational study of donor stem cells for dogs with ... therapy and has performed clinical stem cell therapy for ... to determine if a single injection of donor stem ... help reduce pain and inflammation in the treated joints. ...
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asia-Pacific ... Analytics market in Asia-Pacific with analysis and forecast of ... million in 2014 to $208 million by 2019, at ... 2014 to 2019. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... Calif., March 1, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: ... year ended December 31, 2010. The net loss for ... to $13.4 million during the same period in 2009. The net ... compared to $9.0 million for the year ended December 31, 2009. ...
... NBS ), an international biopharmaceutical company with operations ... Smith, the Company,s Chairman and CEO, will present on Tuesday, ... Annual Analyst Conference. The Conference will be held at the ... York. Dr. Smith will present as part of Track 2: ...
... 2011 /PRNewswire-Asia-FirstCall/ -- ShengdaTech, Inc. ("ShengdaTech" or the "Company") ... nano-precipitated calcium carbonate ("NPCC") in China, today announced that ... Anhui Guo, COO and acting CFO and Mr. A. ... & Renshaw Annual China Investment Conference to be held ...
Cached Biology Technology:MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 2MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 3MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 4MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 5MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 6MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 7NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1 2NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1 3NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1 4ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai 2
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... A large collaborative study has added to the ... a person will be. The research, published by Cell ... of Human Genetics , identifies uncommon and previously unknown ... the genetic architecture of other complex traits. Although ...
... Most agricultural crops require large quantities of ... for growers is finding ways to balance the ... potentially harmful nitrates that can leach into ground ... "low-input" approaches is challenging researchers to identify genotypes ...
... traditionally relied heavily on hand thinning, a necessary but ... costs and a limited workforce, peach and other stone ... string thinners to minimize the need for hand thinning. ... when it was evaluated in four U.S. growing regions; ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
Reactivity: Human...
... EasyComp Transformation Kit is designed for ... cells. Advantages over commonly used transformation ... LiCl methods include:- Cells can be made ... - Competent cell preparation and transformation solutions ...
...
... Enhancer System is used in ... optimize PCR of problematic and/or ... Enhancer Solution with 10X PCRX ... specificity broader magnesium concentration broader ...
Biology Products: